<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00639639</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00003877</org_study_id>
    <secondary_id>CDR0000589624</secondary_id>
    <secondary_id>DUMC-8108-07-1R1</secondary_id>
    <secondary_id>Discretionary Funds</secondary_id>
    <nct_id>NCT00639639</nct_id>
  </id_info>
  <brief_title>Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
  <acronym>ATTAC</acronym>
  <official_title>Anti-Tumor Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed Glioblastoma Multiforme During Recovery From Therapeutic Temozolomide-induced Lymphopenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gary Archer Ph.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may help the body build an effective immune response to kill cancer&#xD;
      cells. Radiation therapy uses high-energy x-rays to kill cancer cells. Drugs used in&#xD;
      chemotherapy, such as temozolomide, work in different ways to stop the growth of cancer&#xD;
      cells, either by killing the cells or by stopping them from dividing. Giving vaccine therapy&#xD;
      together with radiation therapy and chemotherapy may kill more cancer cells.&#xD;
&#xD;
      PURPOSE: This randomized phase I/II trial is studying how well vaccine therapy works in&#xD;
      treating patients with newly diagnosed glioblastoma multiforme recovering from lymphopenia&#xD;
      caused by temozolomide.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To evaluate the feasibility and safety of vaccination with cytomegalovirus (CMV)&#xD;
           pp65-lysosomal-associated membrane protein (LAMP) mRNA-loaded dendritic cells (DCs)&#xD;
           during recovery from therapeutic temozolomide-induced lymphopenia with or without&#xD;
           autologous lymphocyte transfer (ALT) in patients with newly diagnosed glioblastoma&#xD;
           multiforme and who are seropositive or seronegative for CMV.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To assess humoral and cellular immune responses in these patients to CMV pp65-LAMP&#xD;
           mRNA-loaded dendritic cell (CMV-DC) vaccine and to compare the impact of ALT and CMV&#xD;
           seropositivity on these parameters.&#xD;
&#xD;
        -  To determine if vaccination with or without ALT extends total time to progression or&#xD;
           overall survival of these patients when compared to a recent historical cohort.&#xD;
&#xD;
        -  To assess the differential ability of indium In^111-labeled DCs to track to the inguinal&#xD;
           lymph nodes under different skin preparative conditions.&#xD;
&#xD;
        -  To assess the differential ability of ^111In-labeled DCs to track to lymph nodes on the&#xD;
           tumor-bearing and non-tumor-bearing side of the cervical lymph nodes.&#xD;
&#xD;
        -  To characterize immunologic cell infiltrate in recurrent tumors and seek evidence of&#xD;
           antigen escape in recurrent or progressive tumors.&#xD;
&#xD;
      OUTLINE: This is a multicenter study.&#xD;
&#xD;
      Patients undergo leukapheresis no more than 4 weeks after surgical resection to obtain&#xD;
      peripheral blood lymphocytes (PBLs) for human cytomegalovirus (CMV)-autologous lymphocyte&#xD;
      transfer (ALT) and CMV-dendritic cell (DC) generation.&#xD;
&#xD;
      Beginning 2-6 weeks after resection, patients undergo external beam radiotherapy (RT) once&#xD;
      daily, 5 days a week, for up to 7 weeks. Beginning on day 1 of RT, patients receive oral&#xD;
      temozolomide (TMZ) once daily for up to 49 days. Patients with progressive disease during RT,&#xD;
      dependence on steroids above physiologic levels, intolerance to TMZ, or failure to meet cell&#xD;
      release criteria for DCs or PBLs are removed from study.&#xD;
&#xD;
      Beginning within 2-4 weeks after completion of concurrent RT and TMZ, patients resume oral&#xD;
      TMZ once daily on days 1-5. Treatment repeats every 4-6 weeks for up to 6 courses* in the&#xD;
      absence of disease progression or unacceptable toxicity. Beginning on day 19-23 of course 1,&#xD;
      patients also receive an intradermal immunization. Patients are stratified by CMV serology&#xD;
      status (positive vs negative) and are randomized to 1 of 2 vaccine treatment arms.&#xD;
&#xD;
      NOTE: *Patients may receive additional TMZ treatment at the discretion of the patient and&#xD;
      their treating neuro-oncologist.&#xD;
&#xD;
        -  Arm I (DC vaccination plus ALT): Patients receive CMV-ALT IV over 45-90 minutes (course&#xD;
           1 only) and 2 x 10^7 CMV pp65-LAMP mRNA-loaded DC (CMV-DC) vaccine intradermally and&#xD;
           administered in equal portions to each inguinal region. Vaccination repeats every 1-3&#xD;
           weeks for up to 3 doses in the absence of unacceptable toxicity.&#xD;
&#xD;
        -  Arm II (DC vaccination alone): Patients receive CMV-DC vaccine as in arm I. At&#xD;
           approximately 2-6 weeks after the third vaccination, all patients undergo a second&#xD;
           leukapheresis to obtain peripheral blood mononuclear cells for immunologic monitoring&#xD;
           and additional DCs for continued vaccinations. Patients may undergo an additional&#xD;
           leukapheresis if they achieve a positive immunological response to therapy or if they&#xD;
           require additional DCs to be generated due to a prolonged progression-free survival.&#xD;
           Leukapheresis may be performed monthly, but will likely be performed every 4 months&#xD;
           throughout the study to generate enough DCs to continue monthly vaccinations.&#xD;
&#xD;
        -  Additional cohort (GM-CSF): Patients receive CMV-DC vaccine as in arm II, except that&#xD;
           they will also receive GM-CSF in each vaccine. Vaccines continue for a total of 10&#xD;
           unless tumor progression occurs. Patients in this cohort may be enrolled at any point&#xD;
           prior to completion of adjuvant TMZ provided they meet all other eligibility criteria.&#xD;
&#xD;
      Prior to the fourth vaccination, patients in both arms and patients with disease progression&#xD;
      determined prior to the first scheduled vaccination are stratified according to side of&#xD;
      inguinal injection (left vs right) and vaccination skin site preparation (unpulsed DCs vs&#xD;
      tetanus toxoid). Patients are then randomized to 1 of 2 treatment arms.&#xD;
&#xD;
        -  Arm I (unpulsed DCs): Within 6 to 24 hours prior to vaccination, patients undergo skin&#xD;
           site preparation with 1 x 10^6 unpulsed DCs at the vaccination site in one inguinal&#xD;
           region. Patients then receive indium In^111-labeled CMV-DC.&#xD;
&#xD;
        -  Arm II (tetanus toxoid): Within 6 to 24 hours prior to vaccination, patients undergo&#xD;
           vaccination skin site preparation in the opposite inguinal region with tetanus toxoid.&#xD;
           Patients then receive indium In^111-labeled CMV-DC as in arm I.&#xD;
&#xD;
      At the time of progression, patients receive a final intradermal vaccination comprising&#xD;
      ^111In-labeled CMV-DCs at the base of the jaw bilaterally and to the inguinal region, as a&#xD;
      control. Gamma camera images are then taken at 24 and 48 hours after the vaccination to&#xD;
      compare DC migration in the groin to each side of the neck injection sites and to observe&#xD;
      migration from the neck injection sites to the deep and superficial cervical lymph nodes.&#xD;
&#xD;
      After completion of TMZ therapy, patients continue receiving DC vaccinations in the absence&#xD;
      of disease progression (except GM-CSF cohort - total of 10 vaccinations).&#xD;
&#xD;
      Patients undergo blood sample collection periodically for immunologic studies. Samples are&#xD;
      examined for functional CD4 and CD8 immune response of patients by cytokine fluorescent&#xD;
      cytometry; enumeration of pp65 antigen-specific CD8+ T cells by tetramer analysis;&#xD;
      antigen-induced T-cell proliferation; cytokine secretion and quantitative anti-pp65 antibody&#xD;
      concentration in the serum by ELISA; and CMV pp65 quantitation in genomic DNA by reverse&#xD;
      transcriptase-polymerase chain reaction. Patients may also undergo stereotactic biopsy or&#xD;
      tumor resection to confirm tumor progression histologically and to assess immunologic cell&#xD;
      infiltration and pp65 antigen escape at the tumor site by immunohistochemistry and polymerase&#xD;
      chain reaction.&#xD;
&#xD;
      Quality of life is assessed by the self-reported Functional Assessment of Cancer&#xD;
      Therapy-Brain questionnaire at initial leukapheresis, at the first vaccination, after the&#xD;
      third vaccination at the time of post-vaccine leukapheresis, and then with every&#xD;
      even-numbered vaccination thereafter. A neuropsychological assessment is also conducted prior&#xD;
      to the first vaccine and then with every second vaccination thereafter in order to monitor&#xD;
      for any changes in neurocognitive or affective changes.&#xD;
&#xD;
      After completion of study therapy, patients are followed periodically.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Actual">April 15, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility and safety of vaccination with cytomegalovirus pp65-LAMP mRNA-loaded dendritic cells (DCs) with or without autologous lymphocyte transfer</measure>
    <time_frame>26 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Humoral and cellular immune responses</measure>
    <time_frame>26 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>From time of surgery/diagnosis to date of progression.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differential ability of indium In-111-labeled DCs to track to the inguinal lymph nodes under different skin preparative conditions</measure>
    <time_frame>At vaccine # 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differential ability of indium In-111-labeled DCs to track to lymph nodes on the tumor bearing and non-tumor bearing side of the cervical lymph nodes</measure>
    <time_frame>At vaccine # 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunologic cell infiltrate in recurrent tumors</measure>
    <time_frame>At progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evidence of antigen-escape outgrowth in recurrent or progressive tumors</measure>
    <time_frame>At progression</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Malignant Neoplasms of Brain</condition>
  <arm_group>
    <arm_group_label>Arm I (first randomization)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive CMV-ALT IV over 45-90 minutes (course 1 only) and CMV pp65-LAMP mRNA-loaded DC (CMV-DC) vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (first randomization)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive CMV-DC vaccine intradermally and administered in equal portions to each inguinal region. Vaccination repeats every 1-3 weeks for up to 3 doses in the absence of unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm I (second randomization)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 6 to 24 hours prior to vaccination, patients undergo skin site preparation with unpulsed DCs at the vaccination site in one inguinal region. Patients then receive indium In 111-labeled CMV-DC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II (second randomization)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Within 6 to 24 hours prior to vaccination, patients undergo vaccination skin site preparation in the opposite inguinal region with tetanus toxoid. Patients then receive 111 In-labeled CMV-DC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>tetanus toxoid</intervention_name>
    <description>Given by injection</description>
    <arm_group_label>Arm II (second randomization)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous dendritic cells</intervention_name>
    <description>Given intradermally</description>
    <arm_group_label>Arm I (first randomization)</arm_group_label>
    <arm_group_label>Arm I (second randomization)</arm_group_label>
    <arm_group_label>Arm II (first randomization)</arm_group_label>
    <arm_group_label>Arm II (second randomization)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic autologous lymphocytes</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I (first randomization)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histopathologic diagnosis of glioblastoma multiforme&#xD;
&#xD;
               -  Newly diagnosed WHO grade IV disease&#xD;
&#xD;
          -  Underwent definitive resection within the past 4 weeks&#xD;
&#xD;
          -  Residual radiographic contrast enhancement on post-resection CT scan or MRI must not&#xD;
             exceed 1 cm in diameter in two perpendicular axial planes&#xD;
&#xD;
          -  No radiographic or cytologic evidence of leptomeningeal or multicentric disease at any&#xD;
             time prior to vaccination&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  Karnofsky performance status 80-100%&#xD;
&#xD;
          -  Curran Group status I-IV&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No active infection requiring treatment&#xD;
&#xD;
          -  No unexplained febrile (&gt; 101.5ยบ F) illness&#xD;
&#xD;
          -  No known immunosuppressive disease&#xD;
&#xD;
          -  No known HIV infection&#xD;
&#xD;
          -  No unstable or severe intercurrent medical conditions such as severe heart or lung&#xD;
             disease&#xD;
&#xD;
          -  No demonstrated allergy or intolerance to temozolomide for reasons other than&#xD;
             lymphopenia&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior conventional antitumor therapy other than steroids, radiotherapy, or&#xD;
             temozolomide&#xD;
&#xD;
          -  No prior inguinal lymph node dissection&#xD;
&#xD;
          -  No prior radiosurgery, brachytherapy, or radiolabeled monoclonal antibodies&#xD;
&#xD;
          -  No concurrent corticosteroids, with the exception of nasal or inhaled steroids, at a&#xD;
             dose above physiologic levels (defined as &lt; 2 mg of dexamethasone/day)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katherine Peters, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Univeristy Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, Nair SK, Congdon KL, Reap EA, Archer GE, Desjardins A, Friedman AH, Friedman HS, Herndon JE 2nd, Coan A, McLendon RE, Reardon DA, Vredenburgh JJ, Bigner DD, Sampson JH. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015 Mar 19;519(7543):366-9. doi: 10.1038/nature14320. Epub 2015 Mar 11.</citation>
    <PMID>25762141</PMID>
  </results_reference>
  <results_reference>
    <citation>Batich KA, Reap EA, Archer GE, Sanchez-Perez L, Nair SK, Schmittling RJ, Norberg P, Xie W, Herndon JE 2nd, Healy P, McLendon RE, Friedman AH, Friedman HS, Bigner D, Vlahovic G, Mitchell DA, Sampson JH. Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clin Cancer Res. 2017 Apr 15;23(8):1898-1909. doi: 10.1158/1078-0432.CCR-16-2057.</citation>
    <PMID>28411277</PMID>
  </results_reference>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 19, 2008</study_first_submitted>
  <study_first_submitted_qc>March 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2008</study_first_posted>
  <last_update_submitted>January 23, 2021</last_update_submitted>
  <last_update_submitted_qc>January 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Duke University</investigator_affiliation>
    <investigator_full_name>Gary Archer Ph.D.</investigator_full_name>
    <investigator_title>Assistant Professor Neurosurgery</investigator_title>
  </responsible_party>
  <keyword>adult giant cell glioblastoma</keyword>
  <keyword>adult gliosarcoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

